Winner of the Young Investigator Award, ET-16 Conference, Japan 2019
Dr. Arjun Jain has been awarded the Young Investigator Award at the ET-16 conference, Kobe, Japan 2019 for his outstanding research on ET-traps.
ET-traps’ first seed investment round to deliver CKD clinical study
Published in Business section, Cambridge Independent, January 2022
Nominated for the Cambridge Independent Science and Technology Awards, 2019
Dr Arjun Jain has been nominated for the Researcher of the Year Award at the Cambridge Independent Science and Technology Awards, 2019. Read more
Work on ET-traps published in the Business section of Cambridge Independent on 1st May 2019. Read more
ET-traps got featured in an article in the Financial Express.
"Research & therapy", October 25th, 2020. Read more
ET-traps has been shortlisted for the 30th Business Weekly Awards 2020
Venturing forth : ET-traps, Entrepreneurship Centre, Judge Business School, University of Cambridge
A recent article on ET-traps has been featured in the Judge Business School, University of Cambridge website. Read more
Best Endothelin-1 Therapeutic Targeting Company 2020
ET-traps has been awarded at the Global Health & Pharma Biotechnology Awards, 2020
"ET-traps offer hope of tackling diabetes and neurological disorders" Cambridge Independent
ET-traps in the Business Weekly , 12 November
Latest article on ET-traps published in the latest issue (June 2019) of the European Pharmaceutical Manufacturer Magazine. Read more
Latest news on ET-traps also published in the Business Weekly on 25th June 2019. Read more
Accelerate Cambridge Alumni
ET-traps formerly Endotraps is a biotech venture that aims to develop novel therapeutic intervention in a host of different diseases associated with increased endothelin-1 levels. Numerous research has shown that increased endothelin-1 levels are a critical factor in the pathophysiology of these diseases. Our technology could potentially provide a unique treatment option in several areas of unmet medical need. Read more
